Guidance Summary for the Valuation of Medical Product Gifts -In-Kind :

19
A Framework for Rational Decision Making

description

Guidance Summary for the Valuation of Medical Product Gifts -In-Kind :. A Framework for Rational Decision Making. Health Companies. Humanitarian NGOs. Alcon Abbott Laboratories Fund Baxter BD Boehringer Ingelheim Cares Foundation Bristol-Myers Squibb Co. Eli Lilly and Company - PowerPoint PPT Presentation

Transcript of Guidance Summary for the Valuation of Medical Product Gifts -In-Kind :

Page 1: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

A Framework for Rational Decision Making

Page 2: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

2

Health Companies

AlconAbbott Laboratories FundBaxterBDBoehringer Ingelheim Cares FoundationBristol-Myers Squibb Co.Eli Lilly and CompanyGenzymeGlaxoSmithKlineHospira, Inc.Johnson & JohnsonMerck & Co., Inc.Pfizer, Inc.sanofi-aventis US

Humanitarian NGOs

AmeriCaresCatholic Medical Mission BoardDirect Relief InternationalHeart to Heart InternationalInternational Aid, Inc.Map InternationalMercy Medical Corps Mercy ShipsNational Cancer CoalitionMedical Teams InternationalProject HOPEU.S. Fund for UNICEFTulipeWorld Vision

Page 3: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

3

Page 4: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

Seven Components

1. Assessment

2. Appropriateness

3. Quality & Quantity

4. Packaging

5. Transportation

6. Human Resources

7. Evaluation

Why add medical product valuation?

Page 5: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

There are many legitimate approaches to valuation that are socially relevant and ensure compliance with required financial accounting standards.

The project is an effort to find common ground among often disparate opinions.

Goal to create a white paper or standards.

But first, there are three major challenges to address……

Page 6: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :
Page 7: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

Exit price notion, from market participant perspective (ASC 820-10-30-2)

The transaction to sell the asset occurs in the principal market (i.e. provides the greatest volume and level of activity for the asset) or the most advantageous market (i.e. maximizes the amount received from a sale) if a principal market is not available (ASC 820-10-35-5)

They should not be adjusted for transaction costs (ASC 820-10-35-7).

They assume the highest and best use of the asset by market participants (i.e. maximizes the value of the assets) (ASC 820-10-35-10).

Page 8: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

Real Change Takes Time

Page 9: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

Due process means that any person (organization, company, government agency, individual, etc.) with a direct and material interest has a right to participate by:

a) expressing a position and its basis, b) having that position considered, and c) having the right to appeal.

Due process allows for equity and fair play. The following constitute the minimum acceptable due process requirements for the development of consensus.

Page 10: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :
Page 11: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

Principles Standards or guidelines White paper Examples Tools: a decision tree

It is not meant as a replacement for any NPO’s professional financial review and interpretation of GAAP.

Page 12: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

Developed to inform the valuation process used by non-profits to assign a financial value to medical product donations. Also provides a foundation for standards.

Transparency Compliance Relevance Proper documentation Patient centered donations

Page 13: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

There should be a clear and transparent donation valuation framework that complies with all applicable external accounting requirements.

Page 14: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

Valuation frameworks must be GAAP compliant, subject to accounting interpretation within the law, but consistent in application.

Page 15: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

The valuation framework should reflect the wide range of products, sources, markets and recipients.

Page 16: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

The valuation process should be documented through written procedures and practices and published as part of an organization’s financial statements.

Page 17: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

Primary focus should remain on the recipients; the community, the receiving institution, and the patient.

Where there is a conflict between valuation and service to this population, we will make decisions that first do no harm to the recipients, within the law.

Page 18: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

Expansion of Principles into Guidelines/Standards

Public Comment Period

◦Survey on PQMD.org and email

Revisions and Final Comment Period

Publication

Page 19: Guidance Summary  for  the Valuation of  Medical Product Gifts  -In-Kind :

Contact: [email protected]